309 related articles for article (PubMed ID: 37190151)
1. The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy.
Psilopatis I; Garmpis N; Garmpi A; Vrettou K; Sarantis P; Koustas E; Antoniou EA; Dimitroulis D; Kouraklis G; Karamouzis MV; Marinos G; Kontzoglou K; Nonni A; Nikolettos K; Fleckenstein FN; Zoumpouli C; Damaskos C
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190151
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma.
Psilopatis I; Pergaris A; Giaginis C; Theocharis S
Dis Markers; 2021; 2021():7850688. PubMed ID: 34804263
[TBL] [Abstract][Full Text] [Related]
3. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Sanaei M; Kavoosi F
Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
[TBL] [Abstract][Full Text] [Related]
5. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Koutsounas I; Giaginis C; Patsouris E; Theocharis S
World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities.
Psilopatis I; Vrettou K; Fleckenstein FN; Theocharis S
Cells; 2023 Apr; 12(9):. PubMed ID: 37174627
[TBL] [Abstract][Full Text] [Related]
7. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
8. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Takai N; Kira N; Ishii T; Nishida M; Nasu K; Narahara H
Asian Pac J Cancer Prev; 2011; 12(3):575-80. PubMed ID: 21627347
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors in clinical development.
Rosato RR; Grant S
Expert Opin Investig Drugs; 2004 Jan; 13(1):21-38. PubMed ID: 14680450
[TBL] [Abstract][Full Text] [Related]
10. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
[TBL] [Abstract][Full Text] [Related]
11. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Xu W; Liu H; Liu ZG; Wang HS; Zhang F; Wang H; Zhang J; Chen JJ; Huang HJ; Tan Y; Cao MT; Du J; Zhang QG; Jiang GM
Cancer Lett; 2018 Apr; 420():1-13. PubMed ID: 29410023
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Tasoulas J; Giaginis C; Patsouris E; Manolis E; Theocharis S
Expert Opin Investig Drugs; 2015 Jan; 24(1):69-78. PubMed ID: 25216628
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.
Almeida F; Gameiro A; Correia J; Ferreira F
Animals (Basel); 2021 Feb; 11(2):. PubMed ID: 33671894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
